# Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients

> **NCT02474316** · PHASE4 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 366 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** nucleos(t)ide analgoue

## Key facts

- **NCT ID:** NCT02474316
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 366 (ESTIMATED)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474316, "Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02474316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*